Header

Sarcoma Clinical Trials

Category:Adult
Status:Active

Displaying all 26 trials

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 245 total patients ...

Diagnosis: Sarcoma

Phase: 2 / 3

Protocol Number: 16-171

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas

To study the feasibility of reducing the dose of preoperative radiotherapy in MLS (Myxoid Liposarcomas) from 50 Gy to 36 Gy while maintaining comparable clinicopathological responses.

Diagnosis: Sarcoma

Phase: 2

Protocol Number:

A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa

A phase 2 multi-center investigation of efficacy of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa)

Diagnosis: Sarcoma

Phase: 2

Protocol Number:

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with sarcoma that has spread from the primary site to other parts of the body or cann...

Diagnosis: Sarcoma

Phase: 2

Protocol Number: 18-701

Proton or Photon RT for Retroperitoneal Sarcomas

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention. Phase I studies also try to define the appropriate dose of the investiga...

Diagnosis: Sarcoma

Phase: 1 / 2

Protocol Number: 12-100

PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors

The goal of this clinical research study is to learn how PLX9486 may affect cancer cells with certain mutations in the KIT gene, specifically in patients with types of advanced solid tumors includi...

Diagnosis: Sarcoma

Phase: 1 / 2

Protocol Number: 15-122

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with a...

Diagnosis: Sarcoma

Phase: 1 / 2

Protocol Number: 16-154

Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma

This research study is a Phase I clinical trial, which tests the safety of an investigational drug or combination of drugs and also tries to define the appropriate dose of the combination of invest...

Diagnosis: Sarcoma

Phase: 1

Protocol Number: 13-115

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activ...

Diagnosis: Sarcoma

Phase: 1

Protocol Number: 15-495

Effect of High Doses of Radiation on Bone Structure and Metabolism

This study is designed to characterize the effects of high energy radiation on bone breakdown, with a specific interest in reducing the rate of sacral fractures. Although radiation is very importan...

Diagnosis: Sarcoma

Phase: N/A

Protocol Number: 14-208

Effects Of Caloric Restriction On Post-Operative Complications In Sarcoma Patients Treated With Pre-Operative Radiation Therapy

This study is being conducted to decrease the rate of surgical wound complications. The investigators are studying the effects that caloric restriction has on decreasing the rate of surgical wound ...

Diagnosis: Sarcoma

Phase: N/A

Protocol Number: 15-485

Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antineoplastic ...

Diagnosis: Sarcoma

Phase:

Protocol Number: 15-365

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

The purpose of this early (pilot) clinical trial is to test the effects (both good and bad) of chemotherapy and adoptive immunotherapy with T cells engineered to recognize NY-ESO-1 peptide in patie...

Diagnosis: Sarcoma

Phase:

Protocol Number: 15-591

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-153

A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA

This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or b...

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-135

MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Primary Objective: - To assess the efficacy of MGCD516 in patients with advanced liposarcoma by evaluating the progression free rate at 12 weeks as compared historical controls. Secondary Objective...

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-090

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, fol...

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-365

Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery

This phase II trial studies how well atezolizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body ...

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-727

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

This is a two center, 2 arm, Phase II study evaluating the combination of Ribociclib and Everolimus in patients with advanced DDL and LMS who have had at least 1 prior systemic therapy. Patients wi...

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-233

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

This phase II trial studies how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body, nearby tissue or lymph nodes, or cannot...

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-736

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-355

CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorub...

Diagnosis: Sarcoma

Phase:

Protocol Number: 16-626

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma ...

Diagnosis: Sarcoma

Phase:

Protocol Number: 18-707

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts. Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents. Part ...

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-451

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

This is a 2‑arm, randomized, placebo-controlled, double‑blind, international, multicenter study comparing the efficacy of DCC-2618 to placebo in patients who have received treatment with prior anti...

Diagnosis: Sarcoma

Phase:

Protocol Number: 17-671

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patie...

Diagnosis: Sarcoma

Phase:

Protocol Number: 18-713

'